Expertise in
14
conditions

Dr. Antonio Distasi

Hematology
Office
1802 6th Ave S, 
Birmingham, AL 
Offers Telehealth
21 Years of Experience
Expertise in
14
conditions
Office
1802 6th Ave S, 
Birmingham, AL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Antonio Distasi is a Hematologist in Birmingham, Alabama. Dr. Distasi has been practicing medicine for over 21 years is highly rated in 14 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 37 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in AL
Hospital Affiliations
University Of Alabama Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Office
1802 6th Ave S, Birmingham, AL 35233

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase II Study for Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplants From Matched Related Donors
Phase II Study for Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplants From Matched Related Donors
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Device
Study Phase: Not Applicable
Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen
Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug, Procedure
Study Drug: Fludarabine
Study Phase: Phase 2
A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CD24Fc, Methotrexate, Tacrolimus
Study Phase: Phase 3
Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Enrollment Status: Unknown
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drug: EAGD T-cell
Study Phase: Phase 1
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Biological
Study Drug: ProTmune Ex Vivo Programmed Mobilized Peripheral Cells
Study Phase: Phase 1/Phase 2
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)
Enrollment Status: Completed
Publish Date: September 30, 2022
Intervention Type: Drug
Study Drug: Cyclophosphamide
Study Phase: Phase 2
View 5 Less Clinical Trials

37 Total Publications

Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology.
Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: October 09, 2025
Similar Doctors
Expertise in
30
conditions
Dr. Amitkumar Mehta
Hematology
Expertise in
30
conditions
Dr. Amitkumar Mehta
Hematology

University Of Alabama Health Services Foundation PC

2000 6th Ave S, 
Birmingham, AL 
 (0.2 miles away)
205-801-8415
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amitkumar Mehta is a Hematologist in Birmingham, Alabama. Dr. Mehta is highly rated in 30 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Tissue Biopsy.

Andres Torres
Expertise in
23
conditions
Dr. Andres Torres
Hematology | Oncology
Expertise in
23
conditions
Dr. Andres Torres
Hematology | Oncology

UAB Hospital Birmingham

619 19th St S, 
Birmingham, AL 
 (0.1 miles away)
205-996-6074
Languages Spoken:
English
See accepted insurances

Andres Torres is a Hematologist and an Oncologist in Birmingham, Alabama. Dr. Torres is highly rated in 23 conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Breast Cancer, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, and Bone Marrow Aspiration.

Expertise in
23
conditions
Dr. Luciano Costa
Hematology
Expertise in
23
conditions
Dr. Luciano Costa
Hematology

UAB Hospital Birmingham

619 19th St S, 
Birmingham, AL 
 (0.1 miles away)
205-934-4011
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Luciano Costa is a Hematologist in Birmingham, Alabama. Dr. Costa is highly rated in 23 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Plasmacytoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Distasi's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile